MAGE-A4 peptide-MHC antigen binding proteins
US11912771B2 · kind B2 · utility
1Cited by
11References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 9, 2022 |
| Grant date | Feb 27, 2024 |
| Priority date | — |
| Expiry date | Mar 9, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.